S&P 500   3,133.49 (+0.03%)
DOW   27,826.48 (-0.20%)
QQQ   204.25 (+0.17%)
AAPL   269.74 (+0.47%)
FB   200.99 (+0.06%)
MSFT   151.04 (-0.06%)
GOOGL   1,341.22 (-0.12%)
AMZN   1,738.34 (-0.05%)
NVDA   215.98 (+0.93%)
MU   48.90 (+3.03%)
BABA   203.41 (+1.48%)
TSLA   355.83 (+2.00%)
AMD   39.43 (-0.03%)
ACB   2.49 (-1.19%)
F   9.12 (+0.55%)
PRI   134.62 (-0.48%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.06 (+0.66%)
S&P 500   3,133.49 (+0.03%)
DOW   27,826.48 (-0.20%)
QQQ   204.25 (+0.17%)
AAPL   269.74 (+0.47%)
FB   200.99 (+0.06%)
MSFT   151.04 (-0.06%)
GOOGL   1,341.22 (-0.12%)
AMZN   1,738.34 (-0.05%)
NVDA   215.98 (+0.93%)
MU   48.90 (+3.03%)
BABA   203.41 (+1.48%)
TSLA   355.83 (+2.00%)
AMD   39.43 (-0.03%)
ACB   2.49 (-1.19%)
F   9.12 (+0.55%)
PRI   134.62 (-0.48%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.06 (+0.66%)
S&P 500   3,133.49 (+0.03%)
DOW   27,826.48 (-0.20%)
QQQ   204.25 (+0.17%)
AAPL   269.74 (+0.47%)
FB   200.99 (+0.06%)
MSFT   151.04 (-0.06%)
GOOGL   1,341.22 (-0.12%)
AMZN   1,738.34 (-0.05%)
NVDA   215.98 (+0.93%)
MU   48.90 (+3.03%)
BABA   203.41 (+1.48%)
TSLA   355.83 (+2.00%)
AMD   39.43 (-0.03%)
ACB   2.49 (-1.19%)
F   9.12 (+0.55%)
PRI   134.62 (-0.48%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.06 (+0.66%)
S&P 500   3,133.49 (+0.03%)
DOW   27,826.48 (-0.20%)
QQQ   204.25 (+0.17%)
AAPL   269.74 (+0.47%)
FB   200.99 (+0.06%)
MSFT   151.04 (-0.06%)
GOOGL   1,341.22 (-0.12%)
AMZN   1,738.34 (-0.05%)
NVDA   215.98 (+0.93%)
MU   48.90 (+3.03%)
BABA   203.41 (+1.48%)
TSLA   355.83 (+2.00%)
AMD   39.43 (-0.03%)
ACB   2.49 (-1.19%)
F   9.12 (+0.55%)
PRI   134.62 (-0.48%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.06 (+0.66%)
Log in

NASDAQ:PRAN - Prana Biotechnology Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.06
+1.19 (+136.83 %)
(As of 12/11/2019 12:46 PM ET)
Today's Range
$2.06
Now: $2.06
$2.06
50-Day Range
$0.95
MA: $1.41
$2.06
52-Week Range
$1.09
Now: $2.06
$2.91
VolumeN/A
Average Volume130,956 shs
Market Capitalization$18.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.05
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAN
CUSIPN/A
Phone61-3-9349-4906

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$1.40 per share

Profitability

Miscellaneous

Employees14
Market Cap$18.33 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PRAN News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.


Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions

What is Prana Biotechnology's stock symbol?

Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."

Has Prana Biotechnology been receiving favorable news coverage?

Headlines about PRAN stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prana Biotechnology earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Prana Biotechnology.

Who are some of Prana Biotechnology's key competitors?

What other stocks do shareholders of Prana Biotechnology own?

Who are Prana Biotechnology's key executives?

Prana Biotechnology's management team includes the folowing people:
  • Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 64)
  • Ms. Kathryn Andrews, Chief Financial Officer (Age 52)
  • Dr. David A. Stamler, Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 58)
  • Prof. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory Board
  • Dr. Steven D. Targum M.D., Chief Medical Advisor

What is Prana Biotechnology's stock price today?

One share of PRAN stock can currently be purchased for approximately $2.06.

How big of a company is Prana Biotechnology?

Prana Biotechnology has a market capitalization of $18.33 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-6,400,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Prana Biotechnology employs 14 workers across the globe.View Additional Information About Prana Biotechnology.

What is Prana Biotechnology's official website?

The official website for Prana Biotechnology is http://www.pranabio.com/.

How can I contact Prana Biotechnology?

Prana Biotechnology's mailing address is Level 3 460 Bourke Street, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]


MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  244 (Vote Underperform)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel